Targeting Notch signalling pathway of cancer stem cells

Vandana Venkatesh(JSS Academy of Higher Education and Research), Raghu Nataraj(JSS Academy of Higher Education and Research), Gopenath Thangaraj(JSS Academy of Higher Education and Research), Karthikeyan Murugesan(Quest International University Perak), Ashok Gnanasekaran(Quest International University Perak), Shanmukhappa Kaginelli(JSS Academy of Higher Education and Research), Gobianand Kuppanna, Chandrashekrappa Gowdru Kallappa(JSS Academy of Higher Education and Research), Kanthesh M. Basalingappa(JSS Academy of Higher Education and Research)
Stem Cell Investigation
March 1, 2018
Cited by 271Open Access
Full Text

Abstract

Cancer stem cells (CSCs) have been defined as cells within tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. CSCs have been increasingly identified in blood cancer, prostate, ovarian, lung, melanoma, pancreatic, colon, brain and many more malignancies. CSCs have slow growth rate and are resistant to chemotherapy and radiotherapy that lead to the failure of traditional current therapy. Eradicating the CSCs and recurrence, is promising aspect for the cure of cancer. The CSCs like any other stem cells activate the signal transduction pathways that involve the development and tissue homeostasis, which include Notch signaling pathway. The new treatment targets these pathway that control stem-cell replication, survival and differentiation that are under development. Notch inhibitors either single or in combination with chemotherapy drugs have been developed to treat cancer and its recurrence. This approach of targeting signaling pathway of CSCs represents a promising future direction for the therapeutic strategy to cure cancer.


Related Papers

No related papers found

Powered by citation graph analysis